NAD+ Precursors for Cognitive Performance: What NMN and NR Actually Do

Why NAD+ matters for the brain

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, but the brain depends on it more than almost any other organ. The brain constitutes roughly 2% of body weight yet consumes approximately 20% of the body's total energy output. Nearly all of that energy is produced through mitochondrial oxidative phosphorylation — a process that requires NAD+ as a primary electron carrier. Without adequate NAD+, neurons cannot generate sufficient ATP to maintain membrane potentials, release neurotransmitters, or sustain the synaptic activity that underlies cognition.

Beyond energy metabolism, NAD+ serves as a substrate for several enzyme families critical to brain health. Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, reduce neuroinflammation, and support DNA repair. PARP enzymes, which repair single-strand DNA breaks in neurons, consume NAD+ with every repair event. CD38, an NAD+-degrading enzyme that increases with age, is now understood to be a major driver of age-related NAD+ depletion.

The problem is straightforward: NAD+ levels decline substantially with age. Studies in both animal models and human tissue samples consistently show a 40–60% reduction in NAD+ levels between ages 40 and 70. In the brain specifically, this decline correlates with reduced mitochondrial function, impaired DNA repair capacity, decreased sirtuin activity, and the progressive cognitive decline that most people accept as an inevitable feature of aging.

The central question for cognitive enhancement is whether this decline can be reversed — or at least slowed — by supplementing with NAD+ precursors.

The two main precursors: NMN and NR

NAD+ itself is a large molecule that does not cross cell membranes efficiently when taken orally. This means direct NAD+ supplementation is largely ineffective. Instead, the strategy is to provide smaller precursor molecules that cells can absorb and then convert into NAD+ internally. Two precursors have emerged as the most promising candidates, each with a distinct pathway to NAD+ synthesis.

NMN (nicotinamide mononucleotide)

NMN is the immediate precursor to NAD+ in the salvage pathway — the recycling system that produces the majority of cellular NAD+. Once inside the cell, NMN is converted to NAD+ in a single enzymatic step by the enzyme NMNAT. The key question has been whether NMN can enter cells directly or must first be converted to NR extracellularly. Research published in 2019 identified the Slc12a8 transporter, which appears to facilitate direct NMN uptake in the gut and certain tissues, though the extent of this transport in the brain remains under investigation.

NMN is found naturally in small amounts in foods including edamame, broccoli, avocado, and cucumber — though the quantities are far too low to meaningfully raise NAD+ levels. Supplemental NMN is typically dosed at 250–500mg per day.

NR (nicotinamide riboside)

NR sits one step further back in the salvage pathway. It is first converted to NMN by the enzyme nicotinamide riboside kinase (NRK1/NRK2), and then NMN is converted to NAD+. Despite this extra step, NR has one significant advantage in the current landscape: it has a substantially larger body of published human clinical trial data, primarily because ChromaDex (the company behind the NIAGEN brand) has invested heavily in clinical research programmes.

NR was first identified as an NAD+ precursor in 2004 by Charles Brenner's laboratory at the University of Iowa. It enters cells via equilibrative nucleoside transporters, which are widely expressed across tissues including the brain.

How NAD+ decline affects cognitive function

The consequences of falling NAD+ levels in the brain are not subtle. They manifest across multiple systems simultaneously, creating a compounding effect that accelerates cognitive aging.

• Mitochondrial dysfunction: Reduced NAD+ impairs complex I of the electron transport chain, decreasing ATP production per mitochondrion. Neurons compensate by increasing reactive oxygen species (ROS) production, which damages mitochondrial DNA and creates a vicious cycle of declining energy output. This manifests as mental fatigue, slower processing speed, and reduced capacity for sustained cognitive effort — symptoms that are often dismissed as "normal aging."
• Impaired DNA repair: Neurons are post-mitotic — they cannot divide to replace themselves. This makes DNA repair essential for neuronal longevity. PARP1, the primary DNA repair enzyme in neurons, consumes one molecule of NAD+ per repair event. When NAD+ is depleted, PARP1 activity drops, unrepaired DNA damage accumulates, and neurons become increasingly vulnerable to apoptosis.
• Reduced sirtuin activity: SIRT1 and SIRT3 are particularly important for brain health. SIRT1 promotes mitochondrial biogenesis, suppresses NF-kB-driven neuroinflammation, and supports hippocampal synaptic plasticity. SIRT3, located in mitochondria, protects against oxidative stress. Both require NAD+ as a cofactor, and both decline in activity as NAD+ falls.
• Neuroinflammation: NAD+ depletion activates the NLRP3 inflammasome and increases microglial activation — two drivers of chronic neuroinflammation that are strongly associated with Alzheimer's disease, Parkinson's disease, and age-related cognitive decline. Restoring NAD+ levels has been shown to suppress both pathways in animal models.
• Disrupted circadian regulation: NAD+ levels naturally oscillate over a 24-hour cycle, and this oscillation helps regulate circadian clock genes through SIRT1-mediated deacetylation of BMAL1 and PER2. As NAD+ declines with age, circadian regulation weakens, contributing to the sleep disruption that compounds cognitive decline in older adults.

What the human trials show

NR: the ChromaDex NIAGEN research programme

NR has the most extensive human clinical data of any NAD+ precursor, largely driven by ChromaDex's investment in their patented NIAGEN form. The key findings from published trials:

The CHROMAVITA study (2018) was a landmark trial demonstrating that NR supplementation at 1,000mg/day for 6 weeks safely and effectively raised whole blood NAD+ levels by approximately 60% in healthy older adults. This study established the basic pharmacokinetic proof: oral NR reaches systemic circulation and is converted to NAD+ in humans at meaningful levels.

A 2023 randomised, double-blind, placebo-controlled trial published in Aging Cell examined NR (500mg twice daily) in older adults over 12 weeks. Participants showed significantly increased NAD+ metabolite levels, improved markers of mitochondrial function, and reduced circulating inflammatory cytokines. While this trial was not designed to measure cognitive endpoints directly, the mechanistic improvements — better mitochondrial function, lower inflammation — are precisely the pathways through which NAD+ depletion impairs cognition.

A study in middle-aged and older adults found that NR supplementation at 500mg/day for 6 weeks improved walking speed and grip strength — measures of physical function — alongside increased NAD+ levels. The cognitive relevance is indirect but important: physical function and brain health share mitochondrial and inflammatory pathways, and interventions that improve one often benefit the other.

NMN: emerging human evidence

NMN human trials have accelerated significantly since 2021. A Japanese study published in Science (2022) confirmed that oral NMN at 250mg/day safely raised blood NAD+ levels in healthy men. Notably, insulin sensitivity improved — metabolic health being closely linked to cognitive function via shared inflammatory and vascular pathways.

A 2022 randomised controlled trial in older adults found that NMN supplementation at 250mg/day for 12 weeks improved lower limb function and reduced drowsiness, suggesting effects on both physical performance and alertness. Another trial in middle-aged adults demonstrated that NMN (600–900mg/day) improved aerobic capacity and biological markers of aging.

A study specifically examining cognitive endpoints found that NMN supplementation improved certain measures of processing speed and working memory in older adults, though the effect sizes were modest and the sample size was small. These results are promising but require replication in larger, longer trials.

Dosing: how much and when

Based on published human trial data and emerging consensus:

• NR (nicotinamide riboside): 250–500mg per day. Most clinical trials used 300–1,000mg daily, with 500mg being the most common dose showing reliable NAD+ elevation without significant side effects. NIAGEN (ChromaDex) is the most studied form.
• NMN (nicotinamide mononucleotide): 250–500mg per day. Clinical trials have used 250–900mg daily. 250mg appears to be the minimum effective dose for measurable NAD+ elevation; 500mg is a reasonable target for most users.
• Timing: Morning dosing is preferred. NAD+ levels naturally peak in the morning and decline through the day, and supplementing in alignment with this circadian pattern may be more physiologically appropriate. Some users report mild alertness or sleep disruption with evening dosing.
• With or without food: NR is well-absorbed with or without food. Some NMN forms (particularly those without enteric coating) may benefit from being taken on an empty stomach to reduce degradation by gut NAD+-consuming enzymes, though this is debated.
• Cycling: Unlike racetams or stimulant nootropics, there is no established need to cycle NAD+ precursors. NAD+ is an endogenous molecule, and replenishing it does not appear to cause receptor adaptation. Most researchers and long-term users take them continuously.

Safety profile

NAD+ precursors have a reassuringly clean safety profile across all published human trials. NR has been granted GRAS (Generally Recognized As Safe) status by the FDA in the NIAGEN form. NMN has been sold as a supplement in the US, Japan, and China with no significant safety signals.

Commonly reported side effects are mild and infrequent:

• Mild nausea or GI discomfort: Occasionally reported at higher doses (1,000mg+), usually resolving within a few days or with dose reduction.
• Flushing: Rare, and more associated with niacin and nicotinamide than with NR or NMN. If flushing occurs, it typically indicates conversion to nicotinamide rather than a safety concern.
• Mild headache: Occasionally reported during the first week. Usually transient.
• Sleep changes: Some users report increased alertness that can interfere with sleep if taken in the afternoon or evening. Morning dosing resolves this.

One theoretical concern deserves mention: some researchers have raised questions about whether boosting NAD+ could theoretically support the metabolism of existing cancer cells, since tumour cells also depend on NAD+ for rapid proliferation. The current evidence does not support this concern at supplemental doses — in fact, several studies suggest that restoring NAD+ levels supports DNA repair and immune surveillance in ways that may be protective. However, individuals undergoing cancer treatment should consult their oncologist before supplementing.

Forms and brands: what to look for

• NR — NIAGEN (ChromaDex): The gold standard for NR. This is the form used in virtually all published NR clinical trials. ChromaDex licenses NIAGEN to various supplement brands (Tru Niagen being their direct-to-consumer brand). If you choose NR, using a NIAGEN-based product ensures you are getting the same form that was clinically tested.
• NMN — purity matters: Unlike NR, NMN does not have a single dominant patented form. This means quality varies more between manufacturers. Look for products that provide third-party certificates of analysis (COA) confirming purity above 98%, and that use enzymatic production methods rather than chemical synthesis. Brands like ProHealth, DoNotAge, and Renue By Science have established reputations for quality testing.
• Sublingual and liposomal forms: Some manufacturers offer sublingual NMN tablets or liposomal delivery systems, claiming improved bioavailability by bypassing first-pass liver metabolism. The theoretical rationale is sound — NAD+-consuming enzymes in the liver could degrade some orally ingested NMN — but comparative bioavailability studies in humans are limited. Standard oral forms are effective based on the published trial evidence.
• Avoid "NAD+ direct" supplements: Products claiming to provide NAD+ directly (rather than precursors) are unlikely to meaningfully raise intracellular NAD+ levels. The NAD+ molecule is too large to cross cell membranes efficiently when taken orally. Stick with NMN or NR.

Who benefits most

• Adults over 40: This is when NAD+ decline becomes functionally significant. The older you are, the larger the deficit and the more room there is for improvement. A 25-year-old with healthy NAD+ levels has less to gain than a 55-year-old whose levels have dropped by 50%.
• People experiencing age-related mental fatigue: If you notice that sustained cognitive effort has become harder — not a focus issue per se, but a sense that your brain runs out of energy faster than it used to — NAD+ depletion is a plausible contributor, and precursor supplementation may help.
• Those with poor sleep quality: NAD+ decline disrupts circadian regulation through impaired sirtuin activity. If your sleep has deteriorated with age despite good sleep hygiene, restoring NAD+ levels may support circadian function.
• People with high metabolic stress: Chronic overwork, high-intensity exercise without adequate recovery, caloric restriction, and alcohol consumption all increase NAD+ demand. If your lifestyle imposes significant metabolic stress, supplementation may help maintain NAD+ levels that would otherwise be depleted.

For healthy adults under 35 with good sleep, diet, and exercise habits, NAD+ precursors are a lower priority. The deficit is smaller, and the cognitive return on investment is likely less noticeable than optimising fundamentals like sleep, omega-3 intake, and creatine.

Stacking considerations

NAD+ precursors operate at the metabolic infrastructure level rather than the neurotransmitter level, which means they pair well with most cognitive enhancement compounds without interference:

• With creatine: Creatine and NAD+ precursors address brain energy metabolism through complementary pathways — creatine buffers ATP directly, while NAD+ supports ATP production through the electron transport chain. Together they represent the two most direct approaches to improving brain energy availability.
• With omega-3s: DHA provides the structural membrane substrate; NAD+ provides the energy to keep those membranes functioning. This is a foundational stack — structural integrity plus metabolic energy.
• With resveratrol or other sirtuin activators: Resveratrol activates SIRT1, but SIRT1 requires NAD+ as a cofactor. Supplementing a sirtuin activator without ensuring adequate NAD+ is like pressing the accelerator with no fuel. This combination has a strong mechanistic rationale, and some researchers including David Sinclair have advocated for it publicly.
• With TMG (trimethylglycine): NMN and NR metabolism generates nicotinamide, which is methylated for clearance. This process consumes methyl groups, and at higher doses may deplete methylation capacity. Supplementing TMG (500–1,000mg) alongside NAD+ precursors provides methyl donor support and is increasingly recommended in longevity circles.

Related guides

• Sleep & Cognitive Performance — NAD+ supports circadian regulation; optimising sleep is the foundation that amplifies every other intervention.
• Omega-3 & Brain Health — structural membrane support that pairs with NAD+ metabolic energy for a foundational cognitive stack.
• Nootropic Stacks Guide — where NAD+ precursors fit alongside other compounds in a structured cognitive protocol.
• Creatine & Cognitive Performance — the other direct brain energy intervention, complementary to NAD+ via a distinct ATP-buffering mechanism.